Identification of potential serum markers for endometrial cancer using protein expression profiling

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 3, 2010, Pages 475-481

  Takano, Masashi ^a   Kikuchi, Yoshihiro ^b   Asakawa, Takayoshi ^b   Goto, Tomoko ^a   Kita, Tsunekazu ^c   Kudoh, Kazuya ^d   Kigawa, Junzo ^e   Sakuragi, Noriaki ^f   Sakamoto, Masaru ^g   Sugiyama, Toru ^h   Yaegashi, Nobuo ⁱ   Tsuda, Hiroshi ^j   Seto, Hiroshi ^k   Shiwa, Mieko ^l  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b Ohki Memorial Kikuchi Cancer Clinic for Women   (Japan)

^c TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d National Hospital Organization   (Japan)

^e TOTTORI UNIVERSITY HOSPITAL   (Japan)

^f HOKKAIDO UNIVERSITY   (Japan)

^g Kyoundo Hospital   (Japan)

^h IWATE MEDICAL UNIVERSITY   (Japan)

ⁱ TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j KEIO UNIVERSITY   (Japan)

^k Seto Hospital   (Japan)

^l Yokohama Laboratory   (Japan)

more..

Author keywords

Apolipoprotein; Endometrial cancer; Proteomics; Screening; Serum biomarker

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN C1; BIOLOGICAL MARKER; TUMOR MARKER;

ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER STAGING; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION PROCESS; BLOOD; BLOOD ANALYSIS; CARCINOMA; CASE CONTROL STUDY; ENDOMETRIUM TUMOR; ISOLATION AND PURIFICATION; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; PATHOLOGY; PROTEIN MICROARRAY; RECEIVER OPERATING CHARACTERISTIC; VALIDATION STUDY;

BLOOD CHEMICAL ANALYSIS; CARCINOMA; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM STAGING; PROTEIN ARRAY ANALYSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 77449112409     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0680-7     Document Type: Article

References (35)

1. F Amant P Moerman P Neven D Timmerman E Van Limbergen I Vergote 2006 Endometrial cancer Lancet 366 491 505 10.1016/S0140-6736(05)67063-8
2. SJ Chang MF Hou SM Tsai SH Wu LA Hou H Ma TY Shann SH Wu LY Tsai 2007 The association between lipid profiles and breast cancer among Taiwanese women Clin Chem Lab Med 45 1219 1223 10.1515/CCLM.2007.263 1:CAS:528:DC%2BD2sXhtFKjt7nM 17663634 (Pubitemid 47396275)
3. PL Cherchi S Dessole GA Ruiu G Ambrosini M Farina G Capobianco A Ambrosini 1999 The value of serum CA 125 and association CA 125/CA 19-9 in endometrial carcinoma Eur J Gynaecol Oncol 20 315 317 1:STN:280: DyaK1Mvgt1WitA%3D%3D 10475131
4. LM Coussens Z Werb 2002 Inflammation and cancer Nature 420 860 867 10.1038/nature01322 1:CAS:528:DC%2BD38XpsFygtb4%3D 12490959 (Pubitemid 36019639)
5. M Ehmann K Felix D Hartmann M Schnölzer M Nees S Vorderwülbecke R Bogumil MW Büchler H Friess 2007 Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling Pancreas 34 205 214 10.1097/01.mpa.0000250128.57026.b2 1:CAS:528:DC%2BD2sXjs1Glsbw%3D 17312459 (Pubitemid 46294796)
6. M Emoto R Tamura K Shirota T Hachisuga T Kawarabayashi 2002 Clinical usefulness of color Doppler ultrasound in patients with endometrial hyperplasia and carcinoma Cancer 94 700 706 10.1002/cncr.10208 11857302 (Pubitemid 34132298)
7. T Enomoto M Fujita M Inoue T Nomura 1995 Shroyer KR (1995) Alteration of the p53 tumor suppressor gene and activation of c-K-ras-2 protooncogene in endometrial adenocarcinoma from Colorado Am J Clin Pathol 103 224 230 1:STN:280:DyaK2M7lvF2guw%3D%3D 7856567
8. YZ Feng T Shiozawa A Horiuchi HC Shih T Miyamoto H Kashima A Suzuki T Nikaido I Konishi 2005 Intratumoral heterogeneous expression of p53 correlates with p53 mutation, Ki-67, and cyclin A expression in endometrioid-type endometrial adenocarcinomas Virchows Arch 447 816 822 10.1007/s00428-005-0029-9 1:CAS:528:DC%2BD2MXht1KnsLbL 16021509 (Pubitemid 41728869)
9. A Gadducci S Cosio A Carpi A Nicolini AR Genazzani 2004 Serum tumor markers in the management of ovarian, endometrial and cervical cancer Biomed Pharmacother 58 24 38 10.1016/j.biopha.2003.11.003 1:CAS:528: DC%2BD2cXltVKmtg%3D%3D 14739059 (Pubitemid 38117046)
10. H Gadomska B Grzechocińska J Janecki G Nowicka M Powolny L Marianowski 2005 Serum lipids concentration in women with benign and malignant ovarian tumours Eur J Obstet Gynecol Reprod Biol 120 87 90 10.1016/j.ejogrb. 2004.02.045 1:CAS:528:DC%2BD2MXjslKgsrc%3D 15866092 (Pubitemid 40615078)
11. J Guo EC Yang L Desouza G Diehl MJ Rodrigues AD Romaschin TJ Colgan KW Siu 2005 A strategy for high-resolution protein identification in surface-enhanced laser desorption/ionization mass spectrometry: calgranulin A and chaperonin 10 as protein markers for endometrial carcinoma Proteomics 5 1953 1966 10.1002/pmic.200401059 1:CAS:528:DC%2BD2MXkslejsL0%3D 15816004 (Pubitemid 40686239)
12. HL Huang T Stasyk S Morandell H Dieplinger G Falkensammer A Griesmacher M Mogg M Schreiber I Feuerstein CW Huck G Stecher GK Bonn LA Huber 2006 Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/MALDI-TOF/TOF and data validation by routine clinical assays Electrophoresis 27 1641 1650 10.1002/elps.200500857 1:CAS:528: DC%2BD28XkslOks78%3D 16550499
13. I Jacobs RC Bast Jr 1987 The elevation of CA 125 tumor-associated antigen: a review of the literature Hum Reprod 4 1 12
14. Y Kanamori J Kigawa H Itamochi M Shimada M Takahashi S Kamazawa S Sato R Akeshima N Terakawa 2001 Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma Clin Cancer Res 7 892 895 1:CAS:528:DC%2BD3MXjs1elsL0%3D 11309338
15. Y Kanamori J Kigawa H Itamochi H Sultana M Suzuki M Ohwada T Kamura T Sugiyama Y Kikuchi T Kita K Fujiwara N Terakawa 2002 PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy Int J Cancer 100 686 689 10.1002/ijc.10542 1:CAS:528:DC%2BD38XlvFKgsrw%3D 12209607 (Pubitemid 34832979)
16. IK Kolasa A Rembiszewska A Janiec-Jankowska A Dansonka-Mieszkowska AM Lewandowska B Konopka J Kupryjańczyk 2006 PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations Gynecol Oncol 103 692 697 10.1016/j.ygyno.2006.05.007 1:CAS:528:DC%2BD28XhtFegurrO 16793127 (Pubitemid 44602189)
17. KR Kozak F Su JP Whitelegge K Faull S Reddy R Farias-Eisner 2005 Characterization of serum biomarkers for detection of early stage ovarian cancer Proteomics 5 4589 4596 10.1002/pmic.200500093 1:CAS:528:DC%2BD2MXht12nt7vN 16237736 (Pubitemid 41739936)
18. H Lagarda L Catasus R Arguelles X Matias-Guiu J Prat 2001 K-ras mutations in endometrial carcinomas with microsatellite instability J Pathol 193 193 199 10.1002/1096-9896(2000)9999:9999<::AID-PATH769>3.0.CO;2-9 1:CAS:528:DC%2BD3MXhtFGqtbo%3D 11180166 (Pubitemid 32118131)
19. SF Lax B Kendall H Tashiro RJ Slebos L Hedrick 2000 The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways Cancer 88 814 824 10.1002/(SICI)1097-0142(20000215)88:4<814::AID-CNCR12>3.0.CO;2-U 1:CAS:528:DC%2BD3cXhtlGntbk%3D 10679651 (Pubitemid 30091101)
20. Y Minagawa S Sato M Ito Y Onohara S Nakamoto J Kigawa 2005 Transvaginal ultrasonography and endometrial cytology as a diagnostic schema for endometrial cancer Gynecol Obstet Invest 59 149 154 10.1159/000083089 15637434 (Pubitemid 40591479)
21. Y Mizumoto S Kyo N Mori J Sakaguchi S Ohno Y Maida M Hashimoto M Takakura M Inoue 2007 Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis Cancer Sci 98 652 658 10.1111/j.1349-7006.2007.00445.x 1:CAS:528:DC%2BD2sXkvFSktbk%3D 17388789 (Pubitemid 46563440)
22. LE Moore ET Fung M McGuire CC Rabkin A Molinaro Z Wang F Zhang J Wang C Yip XY Meng RM Pfeiffer 2006 Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population Cancer Epidemiol Biomarkers Prev 15 1641 1646 10.1158/1055-9965.EPI-05-0980 1:CAS:528:DC%2BD28Xps1ynt74%3D 16985025 (Pubitemid 44497099)
23. N Mori S Kyo J Sakaguchi Y Mizumoto S Ohno Y Maida M Hashimoto M Takakura M Inoue 2007 Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosiss Cancer Sci 98 1881 1888 10.1111/j.1349-7006.2007.00630.x 1:CAS:528:DC%2BD2sXhsVahtbfE 17924977 (Pubitemid 350002193)
24. GL Mutter MC Lin JT Fitzgerald JB Kum JP Baak JA Lees LP Weng 2000 Eng C (2000) Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers J Natl Cancer Inst 92 924 930 10.1093/jnci/92.11.924 1:CAS:528:DC%2BD3cXksF2qur0%3D 10841828
25. GL Mutter TA Ince JP Baak GA Kust XP Zhou C Eng 2001 Molecular identification of latent precancers in histologically normal endometrium Cancer Res 61 4311 4314 1:CAS:528:DC%2BD3MXktlSqur0%3D 11389050
26. M Navab R Yu N Gharavi W Huang N Ezra A Lotfizadeh GM Anantharamaiah N Alipour BJ Van Lenten ST Reddy D Marelli 2007 High-density lipoprotein: antioxidant and anti-inflammatory properties Curr Atheroscler Rep 9 244 248 10.1007/s11883-007-0026-3 1:CAS:528:DC%2BD2sXhtlWnt7rE 18241620 (Pubitemid 47629072)
27. HB Salvesen I Stefansson EI Kretzschmar P Gruber ND MacDonald A Ryan IJ Jacobs LA Akslen S Das 2004 Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression Int J Oncol 25 1615 1623 1:CAS:528:DC%2BD2MXhsVOrtg%3D%3D 15547698
28. N Sato N Fukushima R Chang H Matsubayashi M Goggins 2006 Differentialand epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers Gastroenterology 130 548 565 10.1053/j.gastro. 2005.11.008 1:CAS:528:DC%2BD28Xit1aks74%3D 16472607 (Pubitemid 43202051)
29. Y Shang 2006 Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis Nat Rev Cancer 6 360 368 10.1038/nrc1879 1:CAS:528: DC%2BD28XjslGitLg%3D 16633364
30. A Tabor HC Watt NJ Wald 2002 Endometrial thickness as a test for endometrial cancer in women with postmenopausal vaginal bleeding Obstet Gynecol 99 663 670 10.1016/S0029-7844(01)01771-9 12039131 (Pubitemid 34246309)
31. S Takano H Yoshitomi A Togawa K Sogawa T Shida F Kimura H Shimizu T Tomonaga F Nomura M Miyazaki 2008 Apolipoprotein C-1 maintains cell survival by preventing from apoptosis in pancreatic cancer cells Oncogene 27 2810 2822 10.1038/sj.onc.1210951 1:CAS:528:DC%2BD1cXltlSgs70%3D 18037960 (Pubitemid 351620452)
32. A Velasco E Bussaglia J Pallares X Dolcet D Llobet M Encinas N Llecha J Palacios J Prat X Matias-Guiu 2006 PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations Hum Pathol 37 1465 1472 10.1016/j.humpath.2006.05.007 1:CAS:528:DC%2BD28XhtFSrt7nL 16949921 (Pubitemid 44584324)
33. EC Yang J Guo G Diehl L DeSouza MJ Rodrigues AD Romaschin TJ Colgan KW Siu 2004 Protein expression profiling of endometrial malignancies reveals a new tumor marker: chaperonin 10 J Proteome Res 3 636 643 10.1021/pr049975z 1:CAS:528:DC%2BD2cXisFaqtb8%3D 15253447 (Pubitemid 39207370)
34. T Yoshizaki T Enomoto R Nakashima Y Ueda H Kanao K Yoshino M Fukumoto Y Yoneda GS Buzard Y Murata 2005 Altered protein expression in endometrial carcinogenesis Cancer Lett 226 101 106 10.1016/j.canlet.2004.11.053 1:CAS:528:DC%2BD2MXmsVaisbs%3D 16039949 (Pubitemid 41039077)
35. Z Zhang RC Bast Jr Y Yu J Li LJ Sokoll AJ Rai JM Rosenzweig B Cameron YY Wang XY Meng A Berchuck C Van Haaften-Day NF Hacker HW de Bruijn AG van der Zee IJ Jacobs ET Fung DW Chan 2004 Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer Cancer Res 64 5882 5890 10.1158/0008-5472.CAN-04-0746 1:CAS:528:DC%2BD2cXmslaks7Y%3D 15313933 (Pubitemid 39095590)